BioSpace News Archive

Tides has have turned for Hemp and CBD in the beauty industry as confusion turns to curiosity. Uncle Bud’s Natural Hemp, the trusted collection of natural, hemp-infused products, is growing rapidly launching new products nearly every month since the brand’s official launch in June 2018.

The National Association for Behavioral Healthcare (NABH) on Tuesday released The High Cost of Compliance: Assessing the Regulatory Burden on Inpatient Psychiatric Facilities, a comprehensive report that examines the burdens that certain regulations impose on the nation’s inpatient psychiatric facilities.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), completed the human trials of its proprietary Rapid Acoustic Pulse (RAP) Device to support the Company’s FDA 510(k) submission.

CompHealth, a national leader in healthcare staffing, and the American Academy of Family Physicians (AAFP) released results from a joint study on the overall happiness of physicians, which finds that most physicians are happy in their careers and personal lives.

New Jersey Innovation Institute (NJII), a New Jersey Institute of Technology (NJIT) Corporation, has signed an Industry Participation Agreement with Pall Corporation (Pall) to support the development of its BioPharmaceutical Innovation iLab.

One Drop, a leader in the development of digital therapeutics solutions for people with diabetes and related conditions, today announced a partnership with Amazon’s exclusive health brand, Choice.

Stanford Medicare Advantage plan seeks sustainable growth and continued innovations to serve seniors in collaboration with Lumeris

Henry Schein Financial Services (HSFS), a subsidiary of Henry Schein, Inc. (Nasdaq: HSIC), today celebrates its 20th anniversary delivering customized financial and business solutions that help oral health and medical practitioners improve operational efficiency.

Proven digital health innovator and investor to help advance the Company’s mission to reshape the pharmaceutical manufacturing landscape

Vibegron met both co-primary endpoints demonstrating highly significant reduction in daily urge urinary incontinence episodes and micturitions, compared to placebo